Previous 10 | Next 10 |
Merus press release ( NASDAQ: MRUS ): Q4 GAAP EPS of -$2.92. Revenue of $41.59M (-0.7% Y/Y) misses by $7.51M . For further details see: Merus GAAP EPS of -$2.92, revenue of $41.59M misses by $7.51M
– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023 ...
As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Petosemtamab clinical update planned for first half of 2023 MCLA-129 clinical update planned for second...
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned fo...
Summary MRUS has traded with wide-reaching volatility over the course of the past 2 years. A series of setbacks on its pipeline conversions has seen a number of rapid selloffs, each resulting in tremendous drawdown. The latest headwind sprouts from the FDA requesting more enrollment...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundber...
Merus N.V. ( NASDAQ: MRUS ) shed ~30% intraday on Thursday after the Dutch biotech said with its Q3 2022 financials that the FDA recommended additional patient enrollment to generate data to support a potential marketing application for bispecific antibody Zenocutuzumab....
Merus press release ( NASDAQ: MRUS ): Q3 GAAP EPS of -$0.53 beats by $0.08 . Revenue of $6.58M (-51.9% Y/Y) misses by $4.42M . As of September 30, 2022, Merus had $372.9 million cash and cash equivalents sufficient to fund company operations beyond 2024. Sh...
The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus (MRUS) Presents at 34th EORTC-NCI-AACR Symposium
Merus N.V. ( NASDAQ: MRUS ) lost ~10% on Wednesday after the Dutch biotech updated initial in-human data for its cancer therapy MCLA-129 from a Phase 1/2 trial involving patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. The readout inclu...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...